Dovitinib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Recurrent Adenoid Cystic Carcinoma of the Salivary Glands

Conditions

Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands, Salivary Gland Cancers, ACC

Trial Timeline

Nov 1, 2012 → Sep 1, 2015

NCT ID

NCT01678105

About Dovitinib

Dovitinib is a phase 2 stage product being developed by Novartis for Recurrent Adenoid Cystic Carcinoma of the Salivary Glands. The current trial status is completed. This product is registered under clinical trial identifier NCT01678105. Target conditions include Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands, Salivary Gland Cancers.

What happened to similar drugs?

4 of 20 similar drugs in Recurrent Adenoid Cystic Carcinoma of the Salivary Glands were approved

Approved (4) Terminated (0) Active (16)

🔄Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3

✅Zopapogene imadenovec (Zopa)PrecigenApproved

🔄E7777 9 mcg/kgEisaiPhase 3

🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3

🔄Chemotherapy + Pembrolizumab + RamucirumabEli LillyPhase 3

🔄Abiraterone Acetate + Bicalutamide + Leuprolide + Prednisone + RelugolixSumitomo PharmaPhase 3

🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01888965	Phase 2	Terminated	Oct 1, 2013	Oct 1, 2014	Colorectal Cancer
NCT01732107	Phase 2	Terminated	Mar 1, 2013	Mar 6, 2017	Bladder Cancer
NCT01769547	Phase 2	Terminated	Mar 1, 2013	Jun 1, 2015	Advanced Malignant Pleural Mesothelioma
NCT01676714	Phase 2	Completed	Feb 1, 2013	Jun 1, 2016	Non-Small Cell Lung Cancer
NCT01753713	Phase 2	Completed	Dec 20, 2012	Sep 20, 2017	Adult Giant Cell Glioblastoma
NCT01266070	Phase 2	Terminated	Nov 1, 2012	Dec 1, 2015	Von Hippel-Lindau Syndrome
NCT01678105	Phase 2	Completed	Nov 1, 2012	Sep 1, 2015	Recurrent Adenoid Cystic Carcinoma of the Salivary Glands
NCT01719549	Phase 2	Completed	Sep 1, 2012	Nov 1, 2016	Gastric Cancer
NCT01791387	Phase 2	UNKNOWN	Mar 1, 2012	Jun 1, 2015	Clear Cell Renal Cell Carcinoma
NCT01262027	Phase 2	Completed	Jan 27, 2012	Nov 25, 2015	Breast Cancer
NCT01443481	Phase 1	Completed	Nov 1, 2011	Oct 1, 2014	Solid Tumors

Competing Products

20 competing products in Recurrent Adenoid Cystic Carcinoma of the Salivary Glands

See all competitors

Product	Company	Stage	Hype Score
Doxorubicin Hydrochloride Liposome Injection	Dr. Reddy's Laboratories	Phase 1	26
KPL-914	Kiniksa Pharmaceuticals	Phase 2	29
KPL-387	Kiniksa Pharmaceuticals	Phase 2	36
Rilonacept + Placebo	Kiniksa Pharmaceuticals	Phase 3	34
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	29
Zopapogene imadenovec (Zopa)	Precigen	Approved	44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	30
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
Ramucirumab + Pembrolizumab	Eli Lilly	Phase 2	39
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	35
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab	Daiichi Sankyo	Phase 1/2	39
Ifinatamab deruxtecan	Daiichi Sankyo	Phase 2	42
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 1	36
PLX3397	Daiichi Sankyo	Phase 2	27
erlotinib + etoposide	Astellas Pharma	Phase 2	27
Drug Combination Therapy	Sun Pharmaceutical	Phase 2	42
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	35
Eribulin Mesylate	Eisai	Pre-clinical	26
Lenvatinib + Everolimus	Eisai	Phase 1/2	32
E7090	Eisai	Phase 2	42